- FDA authorizes StemCells to conduct trial of product candidate in patients with age-related macular degeneration
- Bayer receives approval to begin expanded access program for investigational prostate cancer therapy
- FDA removes clinical hold on trial of Idenix's investigational HCV therapy
- Discovery Labs' aerosol drug delivery system approved
- Merck's Janumet XR approved for type 2 diabetes
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Capecitabine in combination with oxaliplatin efficacious in elderly patients with colon cancer, study shows
Tuesday, March 02 2010 | Comments
What's This?
A treatment combination that includes oral capecitabine plus intravenous oxaliplatin improves disease-free survival in subjects with stage III colon cancer compared with treatment using a bolus 5-fluorouracil/leucovorin (5-FU/LV) regimen, and the benefit appears to be unaffected by patient age, according to study results.The researchers noted that a recent analysis of data from the ACCENT database suggested that newer adjuvant regimens were not associated with significant efficacy benefits versus 5-FU/LV in patients aged 70 years or older, so they examined disease-free survival between the capecitabine plus oxaliplatin (XELOX) and 5-FU/LV regimens in this age group, as well as in those who were younger.
The Phase III NO16968 trial included 1,886 patients with stage III colon cancer who were randomized to receive XELOX or 5-FU/LV. The primary endpoint was disease-free survival.
Overall, disease-free survival for all of the patients was significantly improved with XELOX compared with 5-FU/LV at 3, 4, and 5 years.
Among the patients aged younger than 70 years, disease-free survival after 3 years was 72% for those in the XELOX group, compared with 69% for those in the 5-FU/LV group. The patients aged 70 years or older had disease-free survival after 3 years of 66% if they were treated with XELOX and 60% if they were treated with 5-FU/LV.
However, among the patients in the older age group, the difference in disease-free survival between treatment with XELOX and treatment with 5-FU/LV did not achieve statistical significance. Nonetheless, the researchers concluded that XELOX therapy should be considered on a patient-by-patient basis, regardless of age.
Analysis of overall survival is ongoing.
These data were presented recently in Orlando, Fla., at the American Society of Clinical Oncology's 2010 Gastrointestinal Cancers Symposium.
Comments
Be the first to write a comment for this article!
You must be logged in to post a comment.
- White blood cell count in presence of elevated ESR, CRP level predicts infection status in patients undergoing total hip arthroplasty, researchers report
- AISRS useful in measuring methylphenidate therapy for adults with ADHD
- Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report
- Symptoms of early, delayed puberty demand close clinical attention, in spite of shifting norms for pubertal onset
- Low-dose doxepin improves wake after sleep onset among individuals with primary insomnia, data indicate
- School-based nutrition, exercise intervention program may not maintain BMI decreases through 10 months in overweight students, data indicate
- Careful discharge planning, follow-up vital for high-risk neonates facing hospital discharge, updated AAP guidelines state
- Nissen fundoplication in children with GERD reduces need for antireflux medication, researchers find
- AISRS useful in measuring methylphenidate therapy for adults with ADHD
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
